Hemily Katerine Izaguirre-Flores

Dr. Hemily Katerine Izaguirre-Flores

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2020 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
JPJavier Perez-Garcia
Javier Perez-Garcia
JPJosé María Hernández Pérez
José María Hernández Pérez
Ruperto González-PérezRuperto González-Pérez
Ruperto González-Pérez
OPOlaia Sardon Prado
Olaia Sardon Prado
EMElena Martin-Gonzalez
Elena Martin-Gonzalez
Maria Pino-YanesMaria Pino-Yanes
Maria Pino-Yanes
Asthma exacerbations are a major contributor to the global disease burden, but no significant predictive biomarkers are known. The Genomics and Metagenomics of Asthma Severity (GEMAS) study aims to assess the role of genomics and the microbiome in severe asthma exacerbations. Here, we present the design of GEMAS and the characteristics of patients recruited from March 2018 to March 2020. Different biological samples and demographic and clinical variables were collected from asthma patients recruited by allergy and pulmonary medicine units in several hospitals from Spain. Cases and controls were defined by the presence/absence of severe asthma exacerbations in the past year (oral corticosteroid use, emergency room visits, and/or asthma-related hospitalizations). A total of 137 cases and 120 controls were recruited. After stratifying by recruitment location (i.e., Canary Islands and Basque Country), cases and controls did not differ for most demographic and clinical variables (p > 0.05). However, cases showed a higher proportion of characteristics inherent to asthma exacerbations (impaired lung function, severe disease, uncontrolled asthma, gastroesophageal reflux, and use of asthma medications) compared to controls (p < 0.05). Similar results were found after stratification by recruitment unit. Thereby, asthma patients enrolled in GEMAS are balanced for potential confounders and have clinical characteristics that support the phenotype definition. GEMAS will improve the knowledge of potential biomarkers of asthma exacerbations.

25 August 2026 in Journal of Asthma
Verified
Journal Article
Closed access
MGMiguel Jiménez Gómez
Miguel Jiménez Gómez
CACarlos Almonacid
Carlos Almonacid
MAMARINA BLANCO APARICIO
MARINA BLANCO APARICIO
HIHemily Katerine Izaguirre-Flores
Hemily Katerine Izaguirre-Flores
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
JSJosé Gregorio Soto-Campos
José Gregorio Soto-Campos
A critical step in the management of uncontrolled severe asthma—estimated to affect 3–4% of asthma patients (1)—is the identification of the inflammatory phenotype. Severe asthma is a heterogeneous...

Verified
Journal Article
Open access
PDF file
Ruperto González-PérezRuperto González-Pérez
Ruperto González-Pérez
ILIrene De Lorenzo-García
Irene De Lorenzo-García
HIHemily Katerine Izaguirre-Flores
Hemily Katerine Izaguirre-Flores
HGHéctor González-Expósito
Héctor González-Expósito
SGSara García Gil
Sara García Gil
PPPaloma Poza-Guedes
Paloma Poza-Guedes
Background/Objectives: Severe asthma in routine practice often involves long-standing disease, multimorbidity, and prior biologic failure—settings underrepresented in pivotal tezepelumab trials. This study evaluated 52-week real-world effectiveness and safety of tezepelumab in a highly comorbid, predominantly T2-high, biologic-experienced severe asthma cohort from the Canary Islands. Methods: TEZNERIFE is a multicenter, retrospective study including consecutive adolescents and adults with GINA Step 5 severe uncontrolled asthma treated with tezepelumab 210 mg every 4 weeks for 12 months. Clinical outcomes, lung function, type 2 biomarkers, upper airway symptoms, and Biologics Asthma Response Score (BARS) were assessed at baseline, 26 weeks, and 52 weeks. Results: Fifty-six patients (mean age 53.5 years, 71% female, mean asthma duration 30 years, 84% T2-high; 71% with ≥1 prior biologic) were analyzed. ACT improved from 11.5 ± 3.7 to 15.9 ± 4.7 at 26 weeks and 17.5 ± 4.7 at 52 weeks (both p < 0.0001), while annualized exacerbations declined from 2.79 ± 2.0 to 0.50 ± 0.72 and 0.51 ± 0.89 (both p < 0.0001). Maintenance oral corticosteroid dose fell from 10.2 ± 8.3 to 6.9 ± 2.4 mg/day at 52 weeks (p = 0.014). FEV1% predicted increased from 69.3 ± 19.2% to 75.3 ± 17.7% and 76.2 ± 20.6% (p = 0.004 and p = 0.001), and blood eosinophils decreased from 234 ± 231 to 146 ± 120 and 147 ± 110 cells/µL (p = 0.001 and p = 0.013). At one year, 18.9% and 67.9% were classified as good and intermediate responders by BARS; 13.2% were insufficient responders. Two patients discontinued due to non-serious adverse events, while no treatment-related serious events occurred. Conclusions: In this difficult-to-treat, multimorbid, biologic-experienced population, tezepelumab achieved sustained improvements in asthma control, exacerbations, lung function, eosinophilic inflammation, and corticosteroid exposure over 52 weeks, supporting upstream alarmin inhibition as a versatile strategy in complex severe asthma.

10 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Ruperto González-PérezRuperto González-Pérez
Ruperto González-Pérez
ILIrene De Lorenzo-García
Irene De Lorenzo-García
HIHemily Katerine Izaguirre-Flores
Hemily Katerine Izaguirre-Flores
HGHéctor González-Expósito
Héctor González-Expósito
SGSara García-Gil
Sara García-Gil
PPPaloma Poza-Guedes
Paloma Poza-Guedes
Background/Objectives: Severe asthma in routine practice often involves long-standing disease, multimorbidity, and prior biologic failure, settings underrepresented in pivotal tezepelumab trials. This study evaluated 52 week real world effectiveness and safety of tezepelumab in a highly comorbid, predominantly T2 high, biologic experienced severe asthma cohort from the Canary Islands. Methods: TEZNERIFE is a multicenter, retrospective phase IV study including consecutive adolescents and adults with GINA Step 5 severe uncontrolled asthma treated with tezepelumab 210 mg every 4 weeks for 12 months. Clinical outcomes, lung function, type 2 biomarkers, upper airway symptoms, and Biologics Asthma Response Score (BARS) were assessed at baseline, 26 weeks, and 52 weeks. Results: Fifty six patients (mean age 53.5 years, 71% female, mean asthma duration 30 years, 84% T2 high; 71% with ≥1 prior biologic) were analyzed. ACT improved from 11.5±3.7 to 15.9±4.7 at 26 weeks and 17.5±4.7 at 52 weeks (both p<0.0001), while annualized exacerbations declined from 2.79±2.0 to 0.50±0.72 and 0.51±0.89 (both p<0.0001). Maintenance oral corticosteroid dose fell from 10.2±8.3 to 6.9±2.4 mg/day at 52 weeks (p=0.014). FEV1% predicted increased from 69.3±19.2% to 75.3±17.7% and 76.2±20.6% (p=0.004 and p=0.001), and blood eosinophils decreased from 234±231 to 146±120 and 147±110 cells/µL (p=0.001 and p=0.013). At one year, 18.9% and 67.9% were classified as good and intermediate responders by BARS; 13.2% were insufficient responders. Two patients discontinued due to non serious adverse events while no treatment related serious events occurred. Conclusions: In this difficult to treat, multimorbid, biologic experienced population, tezepelumab achieved sustained improvements in asthma control, exacerbations, lung function, eosinophilic inflammation, and corticosteroid exposure over 52 weeks, supporting upstream alarmin inhibition as a versatile strategy in complex severe asthma.